• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Superconnector
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    Zimmer Biomet Highlights Robotics & Musculoskeletal Product Innovations at 2025 AAHKS Annual Meeting

    10/21/25 7:30:00 AM ET
    $ZBH
    Industrial Specialties
    Health Care
    Get the next $ZBH alert in real time by email

    Company to Spotlight Comprehensive Hip & Knee Portfolios and Latest Advancements in Robotics, Including the mBôs™ System Following Recent Acquisition of Monogram Technologies

    WARSAW, Ind., Oct. 21, 2025 /PRNewswire/ -- Zimmer Biomet Holdings, Inc. (NYSE and SIX: ZBH), a global medical technology leader, today announced that it is highlighting bold innovations across its broad robotics and musculoskeletal portfolio at the 2025 annual meeting of the American Association of Hip and Knee Surgeons (AAHKS).

    (PRNewsfoto/Zimmer Biomet Holdings, Inc.)

    During the meeting, the company's booth will prominently feature its broad knee and hip portfolio of customer-centric solutions and infection solutions, along with the latest robotic technologies and data solutions to meet a vast array of surgeon techniques and preferences. Zimmer Biomet will also showcase the surgeon-guided robotic technology recently acquired through the Monogram Technologies Inc. acquisition.

    "Orthopedics is at a pivotal moment," said Ivan Tornos, Chairman, President and Chief Executive Officer of Zimmer Biomet. "As the population ages and expectations rise, patients are demanding more: less disruption, faster recovery and care that fits their lives. Surgeons need solutions that match this urgency, and that's why we've engineered next-generation hip and knee implants and curated an ecosystem of robotics, digital platforms and AI. This isn't incremental innovation — it's the most ambitious innovation cycle in our company's history, positioning Zimmer Biomet to deliver the industry's most comprehensive and adaptable suite of orthopedic robotics and navigation technologies designed to elevate surgical precision and transform patient outcomes."

    The highlights at the Zimmer Biomet booth (#1206) include:

    Digital and Technology Solutions

    • mBôs™ TKA System: a CT-based, semi-autonomous, total knee arthroplasty (TKA) robotic technology that received U.S. Food and Drug Administration (FDA) 510(k) clearance. A surgeon-guided fully autonomous version of this technology is currently in clinical trials.
    • ROSA® Knee with OptimiZe™: the newest version of the ROSA® Knee System that customizes and looks to enhance the surgeon's experience with personalized and intelligent surgical planning, new positioning, tracking and alignment features to improve accuracy1 and reduce user variability,2 pending U.S. FDA 510(k) clearance.
    • TMINI® Miniature Robotic System: a state-of-the-art miniature, handheld, wireless CT-based robotic system designed to enable accurate and precise implant placement.
    • ZBEdge® Analytics: a data platform that delivers intra-operative, mobility and outcome insights directly on a smartphone application, enabling surgeons to objectively assess performance and understand the potential impact of clinical decisions on patient recovery.
    • mymobility® Care Management Platform: a digital care management platform that delivers continuous data and patient-reported feedback to facilitate care, outcomes and satisfaction about patients' surgical preparation and recovery.

    Knee Reconstruction Technologies

    • Oxford® Cementless Partial Knee: the only FDA-approved mobile cementless partial knee implant in the U.S. that has been shown to be efficient3,4 in the operating room and has been proven to have excellent survivorship5,6 worldwide.
    • Persona® OsseoTi® Keel Tibia: a cementless tibia for TKA with a 3D printed porous tray that provides stable initial and biological fixation and intra-operative versatility.7
    • Persona® SoluTion™ PPS® Femur: a knee implant component designed to serve as an alternative metal for patients with certain metal sensitivities like nickel and cobalt-chrome (Co, Cr, Ni) and bone cement that features a porous coating for cementless fixation and leverages a proprietary surface treatment designed to enhance wear performance.8,9
    • Persona IQ® The Smart Knee®: a first-to-world smart knee implant that captures patient-specific gait and range of motion metrics directly from the knee during patient monitoring to provide post-operative recovery insights10,11 and trends, allowing care teams to monitor and personalize the TKA patient experience.10-12

    Hip Reconstruction Technologies

    • Z1® Femoral Hip System: offers an expansive size range and three distinct neck options designed to address a variety of patient anatomies and reconstructive needs.
    • OrthoGrid Hip AI®: an AI-powered, fluoroscopy-based technology that provides direct anterior hip surgeons with intuitive and instantaneous intra-operative tools to assist surgeons in achieving the desired surgical outcomes for component positioning.13
    • HAMMR® Automated Hip Impaction System: designed to address surgeon strain, fatigue and repetitive motion associated with the traditional mallet.

    For more information about Zimmer Biomet events at 2025 AAHKS, visit https://www.zimmerbiomet.com/en/aahks2025.html.

    About Zimmer Biomet

    Zimmer Biomet is a global medical technology leader with a comprehensive portfolio designed to maximize mobility and improve health. We seamlessly transform the patient experience through our innovative products and suite of integrated digital and robotic technologies that leverage data, data analytics and artificial intelligence. 

    With 90+ years of trusted leadership and proven expertise, Zimmer Biomet is positioned to deliver the highest quality solutions to patients and providers. Our legacy continues to come to life today through our progressive culture of evolution and innovation. 

    For more information about our product portfolio, our operations in 25+ countries and sales in 100+ countries or about joining our team, visit www.zimmerbiomet.com or follow on LinkedIn at www.linkedin.com/company/zimmerbiomet or X at www.x.com/zimmerbiomet. 

    Important Safety Information for Oxford Cementless Partial Knee:

    The Oxford® Cementless Partial Knee System is indicated for use in unilateral knee procedures with osteoarthritis or avascular necrosis limited to the medial compartment of the knee. It is intended to be implanted without the application of bone cement for patients whose clinical condition would benefit from a shorter surgical time compared to the cemented implant. The Oxford Partial Knee is not indicated for use in the lateral compartment or for patients with ligament deficiency, or for use in simultaneous bilateral surgery or planned staged bilateral procedures. Potential risks include, but are not limited to, loosening, dislocation, fracture, wear and infection, any of which can require additional surgery. For a full list of product indications, contraindications and warnings, please see the associated product Instructions For Use (IFU).

    Cautionary Statement Regarding Forward-Looking Statements

    This news release contains forward-looking statements within the meaning of the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Forward-looking statements include, but are not limited to, statements concerning Zimmer Biomet's expectations, plans, prospects, and product and service offerings, including new product launches and potential clinical successes. Such statements are based upon the current beliefs and expectations of management and are subject to significant risks, uncertainties and changes in circumstances that could cause actual outcomes and results to differ materially. For a list and description of some of such risks and uncertainties, see Zimmer Biomet's periodic reports filed with the U.S. Securities and Exchange Commission (SEC). These factors should not be construed as exhaustive and should be read in conjunction with the other cautionary statements that are included in Zimmer Biomet's filings with the SEC. Forward-looking statements speak only as of the date they are made, and Zimmer Biomet disclaims any intention or obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise. Readers of this news release are cautioned not to rely on these forward-looking statements, since there can be no assurance that these forward-looking statements will prove to be accurate. This cautionary statement is applicable to all forward-looking statements contained in this news release.

    Laboratory and animal studies are not necessarily indicative of clinical performance.

    THINK Surgical and TMINI are trademarks of THINK Surgical, Inc.

    Persona IQ:

    The objective kinematic data generated by the CSE with CHIRP System are not intended to support clinical decision-making and have not been shown to provide any clinical benefit

    Contacts:

     

    Media

    Troy Kirkpatrick

    614-284-1926

    [email protected]

     

    Kirsten Fallon

    781-779-5561

    [email protected]

    Investors

    David DeMartino

    646-531-6115

    [email protected]

     

    Zach Weiner

    908-591-6955

    [email protected]

    References:

    1 Data on File. DVaR-DS250106-01 ROSA Knee System v1.5 Validation Report.

    2 Data on File. FER-EMS230714-01 Formative Evaluation Report - July Lab 2023.

    3 Pandit, H., et al. "Improved fixation in cementless unicompartmental knee replacement: five-year results of a randomized controlled trial." JBJS 95.15 (2013): 1365-1372.

    4 Stempin R, Kaczmarek W, Stempin K, Dutka J. Midterm Results of Cementless and Cemented Unicondylar Knee Arthroplasty with Mobile Meniscal Bearing: A Prospective Cohort Study. Open Orthop J. 2017 Oct 31;11:1173-1178. doi: 10.2174/1874325001711011173. PMID: 29290853; PMCID: PMC5721307.

    5 NJR- UK . The National Joint Registry 22st Annual Report 2025 London, 2024 [Available from: https://reports.njrcentre.org.uk/Portals/0/PDFdownloads/NJR%2022nd%20Annual%20Report%202025_Knees.pdf.

    6 AOANJRR. Australian Orthopaedic Association National Joint Replacement Registry (AOANJRR). Hip, Knee & Shoulder Arthroplasty: 2023 Annual Report Adelaide, AOA2024 [updated 2024. Available from: https://aoanjrr.sahmri.com/documents/10180/1798900/AOANJRR+2024+Annual+Report.pdf/9d0bfe03-2282-8fc8-a424-b8d9abb82b1f?t=1727666185313.

    7 Mueller J.K., et al. Persona OsseoTi Keel Tibia Provides Stable Initial Fixation 4027.2-GLBL-en. November 2022.

    8 Improved Abrasion Resistance of Nitrogen-Hardened Titanium Alloy Surfaces. Current Topics in Orthopaedic Technology. Zimmer. Vol. 3, No. 6 (1991).

    9 Zimmer ZRR_WA_2537_12.

    10 Cushner FD, Yergler J, ElashoffB, Aubin PM, VertaP, Scuderi GR. Staying Ahead of the Curve: The Case for Recovery Curves in Total Knee Arthroplasty. The Journal of Arthroplasty. 2024;doi:10.1016/j.arth.2024.07.039

    11 Cushner FD, Sculco PK, Long WJ. The Talking Knee Is a Reality: What Your Knee Can Tell You After Total Knee Arthroplasty. J OrthopaedicExperience and Innovation. 2022;2022

    12 Cushner FD, Schiller P, Gross J, Mueller JK, Hunter W. A Total Knee Arthroplasty Prosthesis Capable of Remote Patient Monitoring. OrthopaedicProceedings. 2021/06/01 2021;103-B(SUPP_9):18-18 doi:10.1302/1358-992X.2021.9.018

    13 Cardenas JM, Gordon D, Waddell BS, Kitziger KJ, Peters PC Jr, Gladnick BP. Does Artificial Intelligence Outperform Humans Using Fluoroscopic-Assisted Computer Navigation for Total Hip Arthroplasty? Arthroplasty Today. 2024 May 27;27:101410. doi: 10.1016/j.artd.2024.101410. PMID: 38840694; PMCID: PMC11150909.

    Cision View original content to download multimedia:https://www.prnewswire.com/news-releases/zimmer-biomet-highlights-robotics--musculoskeletal-product-innovations-at-2025-aahks-annual-meeting-302589481.html

    SOURCE Zimmer Biomet Holdings, Inc.

    Get the next $ZBH alert in real time by email

    Crush Q3 2025 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $ZBH

    DatePrice TargetRatingAnalyst
    11/6/2025$100.00Overweight → Neutral
    Analyst
    9/18/2025$130.00Buy
    Rothschild & Co Redburn
    7/15/2025$135.00Neutral → Buy
    Roth Capital
    12/17/2024$125.00 → $128.00Neutral → Overweight
    Analyst
    9/10/2024Peer Perform
    Wolfe Research
    7/1/2024$140.00 → $115.00Overweight → Neutral
    Piper Sandler
    5/30/2024$129.00Neutral
    Goldman
    5/21/2024$150.00Hold → Buy
    Argus
    More analyst ratings

    $ZBH
    SEC Filings

    View All

    SEC Form 10-Q filed by Zimmer Biomet Holdings Inc.

    10-Q - ZIMMER BIOMET HOLDINGS, INC. (0001136869) (Filer)

    11/5/25 4:06:05 PM ET
    $ZBH
    Industrial Specialties
    Health Care

    Zimmer Biomet Holdings Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

    8-K - ZIMMER BIOMET HOLDINGS, INC. (0001136869) (Filer)

    11/5/25 6:30:25 AM ET
    $ZBH
    Industrial Specialties
    Health Care

    SEC Form 8-K filed by Zimmer Biomet Holdings Inc.

    8-K - ZIMMER BIOMET HOLDINGS, INC. (0001136869) (Filer)

    10/7/25 4:10:58 PM ET
    $ZBH
    Industrial Specialties
    Health Care

    $ZBH
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Exec VP, CFO Upadhyay Suketu covered exercise/tax liability with 4,731 shares and converted options into 10,632 shares, increasing direct ownership by 12% to 54,754 units (SEC Form 4)

    4 - ZIMMER BIOMET HOLDINGS, INC. (0001136869) (Issuer)

    11/12/25 4:07:41 PM ET
    $ZBH
    Industrial Specialties
    Health Care

    SEC Form 4 filed by Exec VP, CFO Upadhyay Suketu

    4 - ZIMMER BIOMET HOLDINGS, INC. (0001136869) (Issuer)

    11/3/25 5:42:29 PM ET
    $ZBH
    Industrial Specialties
    Health Care

    SEC Form 4 filed by Director Shapiro Louis

    4 - ZIMMER BIOMET HOLDINGS, INC. (0001136869) (Issuer)

    10/2/25 5:20:07 PM ET
    $ZBH
    Industrial Specialties
    Health Care

    $ZBH
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Zimmer Biomet downgraded by Analyst with a new price target

    Analyst downgraded Zimmer Biomet from Overweight to Neutral and set a new price target of $100.00

    11/6/25 8:47:26 AM ET
    $ZBH
    Industrial Specialties
    Health Care

    Rothschild & Co Redburn initiated coverage on Zimmer Biomet with a new price target

    Rothschild & Co Redburn initiated coverage of Zimmer Biomet with a rating of Buy and set a new price target of $130.00

    9/18/25 8:46:50 AM ET
    $ZBH
    Industrial Specialties
    Health Care

    Zimmer Biomet upgraded by Roth Capital with a new price target

    Roth Capital upgraded Zimmer Biomet from Neutral to Buy and set a new price target of $135.00

    7/15/25 8:30:57 AM ET
    $ZBH
    Industrial Specialties
    Health Care

    $ZBH
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Jafry Syed A. bought $223,641 worth of shares (2,135 units at $104.75), increasing direct ownership by 111% to 4,060 units (SEC Form 4)

    4 - ZIMMER BIOMET HOLDINGS, INC. (0001136869) (Issuer)

    11/13/23 4:02:02 PM ET
    $ZBH
    Industrial Specialties
    Health Care

    Begley Christopher B bought $117,114 worth of shares (1,000 units at $117.11), increasing direct ownership by 39% to 3,540 units (SEC Form 4)

    4 - ZIMMER BIOMET HOLDINGS, INC. (0001136869) (Issuer)

    9/29/23 4:05:41 PM ET
    $ZBH
    Industrial Specialties
    Health Care

    $ZBH
    Financials

    Live finance-specific insights

    View All

    Zimmer Biomet Announces Third Quarter 2025 Financial Results

    Third quarter net sales of $2.001 billion increased 9.7% on a reported basis, 8.6% on a constant currency1 basis and 5.0% on an organic constant currency1 basisThird quarter diluted earnings per share were $1.16; adjusted1 diluted earnings per share were $1.90, an increase of 9.2%For full-year 2025, Company maintains reported revenue growth guidance, reflecting the latest currency expectations, and narrows constant currency1 and organic constant currency1 revenue growth guidanceWARSAW, Ind., Nov. 5, 2025 /PRNewswire/ -- Zimmer Biomet Holdings, Inc. (NYSE and SIX: ZBH) today reported financial results for the quarter ended September 30, 2025.  The Company reported third quarter net sales of $

    11/5/25 6:30:00 AM ET
    $ZBH
    Industrial Specialties
    Health Care

    Zimmer Biomet Completes Acquisition of Monogram Technologies

    Transaction creates the broadest, most flexible portfolio of orthopedic robotics and navigation technologies, including pathway towards the first fully autonomous robotic technology for orthopedic procedures  WARSAW, Ind., Oct. 7, 2025 /PRNewswire/ -- Zimmer Biomet Holdings, Inc. (NYSE and SIX: ZBH) ("Zimmer Biomet"), a global medical technology leader, today announced it has completed the acquisition of Monogram Technologies Inc. ("Monogram"), an AI-driven, next-generation orthopedic robotics company. Monogram's surgeon-guided semi- and fully autonomous robotic technologies a

    10/7/25 9:00:00 AM ET
    $ZBH
    Industrial Specialties
    Health Care

    Zimmer Biomet Announces Webcast and Conference Call of Third Quarter 2025 Financial Results

    WARSAW, Ind., Oct. 3, 2025 /PRNewswire/ -- Zimmer Biomet Holdings, Inc. (NYSE and SIX: ZBH) today announced its third quarter earnings conference call will be webcast on Wednesday, November 5, 2025 at 8:30 a.m. ET. A news release detailing the quarterly results will be made available that day at 6:30 a.m. ET. The live audio webcast can be accessed via Zimmer Biomet's Investor Relations website at https://investor.zimmerbiomet.com. It will be available for replay following the conference call. Individuals in the U.S. and Canada who wish to dial into the conference call may do s

    10/3/25 7:30:00 AM ET
    $ZBH
    Industrial Specialties
    Health Care

    $ZBH
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13G filed by Zimmer Biomet Holdings Inc.

    SC 13G - ZIMMER BIOMET HOLDINGS, INC. (0001136869) (Subject)

    11/14/24 1:22:34 PM ET
    $ZBH
    Industrial Specialties
    Health Care

    Amendment: SEC Form SC 13G/A filed by Zimmer Biomet Holdings Inc.

    SC 13G/A - ZIMMER BIOMET HOLDINGS, INC. (0001136869) (Subject)

    11/13/24 1:44:56 PM ET
    $ZBH
    Industrial Specialties
    Health Care

    SEC Form SC 13G filed by Zimmer Biomet Holdings Inc.

    SC 13G - ZIMMER BIOMET HOLDINGS, INC. (0001136869) (Subject)

    2/14/24 10:02:59 AM ET
    $ZBH
    Industrial Specialties
    Health Care

    $ZBH
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Zimmer Biomet to Present at the Annual Jefferies Global Healthcare Conference in London

    WARSAW, Ind., Nov. 7, 2025 /PRNewswire/ -- Zimmer Biomet Holdings, Inc. (NYSE and SIX: ZBH), a global medical technology leader, today announced that members of the Zimmer Biomet management team will be presenting at the Annual Jefferies Global Healthcare Conference in London on Tuesday, Nov. 18, 2025, at Noon GMT (7 a.m. ET). A live webcast of the presentation can be accessed via Zimmer Biomet's Investor Relations website at https://investor.zimmerbiomet.com. The webcast will be archived for replay following the conference. About Zimmer BiometZimmer Biomet is a global medical

    11/7/25 7:30:00 AM ET
    $ZBH
    Industrial Specialties
    Health Care

    Zimmer Biomet Announces Third Quarter 2025 Financial Results

    Third quarter net sales of $2.001 billion increased 9.7% on a reported basis, 8.6% on a constant currency1 basis and 5.0% on an organic constant currency1 basisThird quarter diluted earnings per share were $1.16; adjusted1 diluted earnings per share were $1.90, an increase of 9.2%For full-year 2025, Company maintains reported revenue growth guidance, reflecting the latest currency expectations, and narrows constant currency1 and organic constant currency1 revenue growth guidanceWARSAW, Ind., Nov. 5, 2025 /PRNewswire/ -- Zimmer Biomet Holdings, Inc. (NYSE and SIX: ZBH) today reported financial results for the quarter ended September 30, 2025.  The Company reported third quarter net sales of $

    11/5/25 6:30:00 AM ET
    $ZBH
    Industrial Specialties
    Health Care

    Zimmer Biomet Announces FDA Breakthrough Designation for World's First Iodine-Treated Total Hip Replacement System

    Prioritized Regulatory Review Process in the U.S. Follows Japan PMDA Approval in September WARSAW, Ind., Oct. 28, 2025 /PRNewswire/ -- Zimmer Biomet Holdings, Inc. (NYSE and SIX: ZBH), a global medical technology leader, today announced the U.S. Food and Drug Administration (FDA) has granted Breakthrough Device Designation for the company's first-to-world iodine-treated total hip replacement system. This is the first product in Zimmer Biomet history to receive this designation. Iodine technology integrates a controlled-release iodine surface treatment into the iTaperloc® Compl

    10/28/25 7:30:00 AM ET
    $ZBH
    Industrial Specialties
    Health Care

    $ZBH
    Leadership Updates

    Live Leadership Updates

    View All

    Zimmer Biomet Announces New Chief Medical Advisors to Help Improve Standard of Musculoskeletal Care

    Dr. Jonathan M. Vigdorchik Named Chief Medical Technology Advisor, Adult Reconstruction and Hip Implants Dr. Anand M. Murthi Appointed Chief Medical Advisor, Shoulder, Sports, Extremities, and Trauma (S.E.T.) WARSAW, Ind., Aug. 28, 2025 /PRNewswire/ -- Zimmer Biomet Holdings, Inc. (NYSE and SIX: ZBH), a global medical technology leader, today announced the appointments of Jonathan M. Vigdorchik, MD, as Chief Medical Technology Advisor focused on Adult Reconstruction and Hip Implants, and Anand M. Murthi, MD, FAAOS, as Chief Medical Advisor, Shoulder, Sports, Extremities, and Trauma (S.E.T.). As strategic advisors, Drs. Vigdorchik and Murthi will leverage their extensive clinical experience t

    8/28/25 7:30:00 AM ET
    $ZBH
    Industrial Specialties
    Health Care

    Zimmer Biomet Appoints Kevin Thornal as Group President, Global Businesses and the Americas

    WARSAW, Ind., May 27, 2025 /PRNewswire/ -- Zimmer Biomet Holdings, Inc. (NYSE and SIX: ZBH), a global medical technology leader, today announced the appointment of Kevin Thornal as Group President, Global Businesses and the Americas. Reporting to Chairman-Elect, President and CEO Ivan Tornos, Mr. Thornal will join the Company on July 1, 2025 to oversee the Americas commercial organization and lead business strategy and execution for its global Knees, Hips, S.E.T. and Data, Technology, and Enabling Solutions units. "Kevin is an incredible addition to our leadership team at an e

    5/27/25 7:30:00 AM ET
    $ZBH
    Industrial Specialties
    Health Care

    Zimmer Biomet Names Kristen Cardillo as Senior Vice President, Chief Communications Officer

    WARSAW, Ind., March 6, 2025 /PRNewswire/ -- Zimmer Biomet Holdings, Inc. (NYSE and SIX: ZBH), a global medical technology leader, today announced the appointment of Kristen Cardillo as Senior Vice President, Chief Communications Officer. Reporting to President and CEO Ivan Tornos, Ms. Cardillo will join the Company on March 10, 2025, to lead Zimmer Biomet's global communications strategy, enhancing engagement with key stakeholders and amplifying the Company's position as a leader in MedTech. "Kristen's expertise in shaping compelling corporate narratives and leading high-impac

    3/6/25 7:30:00 AM ET
    $ZBH
    Industrial Specialties
    Health Care